Yanjun Chen; Mingwei Wei; Xiaoteng Xu; Yunfeng Shi; Shixuan Zhang; Chenhao Wang; Qi Liang; Xue Guo; Hongxing Pan; Yanjun Chen; Mingwei Wei; Xiaoteng Xu; Yunfeng Shi; Shixuan Zhang; Chenhao Wang; Qi Liang; Xue Guo; Hongxing Pan

doi:10.46234/ccdcw2025.210

[1]

Qin XA, Liu K, Fu T, Song SX, Zhao CX, Li ZZ, et al. Global burden, trends, and predictions of rabies: an analysis from the Global Burden of Disease Study 1990-2019 and projections for 2030. J Public Health (Berl) 2025;33(1):69 − 78. https://doi.org/10.1007/s10389-023-01971-9.

[2]

Lodha L, Manoor Ananda A, Mani RS. Rabies control in high-burden countries: role of universal pre-exposure immunization. Lancet Reg Health Southeast Asia 2023;19:100258. https://doi.org/10.1016/j.lansea.2023.100258.

[3]

Verdoes L, Luppino FS, Wallinga J, Visser LG. Delayed rabies post-exposure prophylaxis treatment among Dutch travellers during their stay abroad: a comprehensive analysis. J Travel Med 2021;28(3):taaa240. https://doi.org/10.1093/jtm/taaa240.

[4]

World Health Organization. Rabies vaccines: WHO position paper, April 2018 - recommendations. Vaccine 2018;36(37):5500 − 3. https://doi.org/10.1016/j.vaccine.2018.06.061.

[5]

Shi N, Zhang Y, Zheng H, Zhu Z, Wang D, Li S, et al. Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects. Hum Vaccin Immunother. 2017;13(6):1 − 8 https://doi.org/10.1080/21645515.2017.1279770.

[6]

National Medical Products Administration . Guiding principles for adverse event grading standards in clinical trials of prophylactic vaccines. https://clinregs.niaid.nih.gov/sites/default/files/documents/china/NMPA-No102-2019_Google-Translation.pdf. [2025-5-21].

[7]

Jin F, Zhu L, Wang YP, Qin GQ, Tian Y, Xie YH, et al. Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic. Vaccine 2024;42(23):126059. https://doi.org/10.1016/j.vaccine.2024.06.026.

[8]

Kang G, Lakhkar A, Bhamare C, Dharmadhikari A, Narwadkar J, Kanujia A, et al. Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure. Lancet Reg Health Southeast Asia 202316;100207. http://dx.doi.org/10.1016/j.lansea.2023.100207.

[9]

Zhang W, Guo YF, She F, Liu SQ, Du X, Liu HS. Analysis of factors influencing the course of rabies vaccinations: one year study on compliance of rabies vaccination regimens in Haidian District of Beijing. Patient Prefer Adherence 2022;16:2913 − 20. https://doi.org/10.2147/PPA.S378999.

[10]

Kessels J, Tarantola A, Salahuddin N, Blumberg L, Knopf L. Rabies post-exposure prophylaxis: a systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course. Vaccine 2019;37 Suppl 1:A107-17. http://dx.doi.org/10.1016/j.vaccine.2019.01.041.